XML 64 R52.htm IDEA: XBRL DOCUMENT v3.22.4

Share Capital (Tables)

9 Months Ended

Dec. 31, 2022

Equity [Abstract]

Summary of Issuances of Stock Other

During the nine months ended December 31, 2022, the Company issued the following common shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions:

		Number of common shares				Share capital				Share based reserve
Jetty Agreements			8,426,539			$	59,013			$	-
HSCP Holders pursuant to Amended TRA			5,648,927				20,630				-
Completion of acquisition milestones			222,421				1,379				(1,379	)
Other issuances			237,802				1,209				(353	)
Total			14,535,689			$	82,231			$	(1,732	)

For the three and nine months ended December 31, 2022, the Company also issued 8,692,128 common shares with a value of $26,506 relating to its redemption of the redeemable noncontrolling interest in BioSteel. The redemption increases the Company's interest in BioSteel from 78.6% to 90.3%.

During the nine months ended December 31, 2021, the Company issued the following common shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions:

		Number of common shares				Share capital				Share based reserve
Acquisition of Supreme Cannabis			9,013,400			$	260,668			$	-
Completion of acquisition milestones			1,295,285				29,276				(29,721	)
Other issuances			351,252				6,630				(405	)
Total			10,659,937			$	296,574			$	(30,126	)

Summary of Warrants

		Number of whole warrants				Average exercise price				Warrant value
Balance outstanding at March 31, 20221			128,193,047			$	58.04			$	2,581,788
Expiry of warrants			-				-				-
Balance outstanding at December 31, 20221			128,193,047			$	58.04			$	2,581,788

1 This balance excludes the Tranche C Warrants (as defined below), which represent a derivative liability and have nominal value. See Note 29.

		Number of whole warrants				Average exercise price				Warrant value
Balance outstanding at March 31, 20211			127,073,136			$	58.33			$	2,568,438
Supreme Cannabis warrants			1,265,742				25.61				13,350
Expiry of warrants			(145,831	)			32.61				-
Balance outstanding at December 31, 20211			128,193,047			$	58.04			$	2,581,788

1 This balance excludes the Tranche C Warrants, which represent a derivative liability and have nominal value. See Note 29.

X

- References

No definition available.

+ Details

Name:	us-gaap_EquityAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the equity interest issued or issuable in a business acquisition (or series of individually immaterial business acquisitions) planned, initiated, or completed during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479

+ Details

Name:	us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section S99
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775

+ Details

Name:	us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration